---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045083"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:51:33.176904+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon

## Summary
- Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.
- Cash and cash equivalents $13.0M as of Sep 30, 2024, down from $26.4M at Dec 31, 2023; working capital $12.3M.
- R&D expenses $3.2M (down from $4.2M); G&A $1.8M (stable).
- Expects topline results from Phase 2a influenza A challenge study (CC-42344) by year end 2024.
- Topline results from Phase 1 norovirus/coronavirus study (CDI-988) expected late 2024/early 2025; cash sufficient for 12 months.

## SEC filing metadata
- accession: 0001493152-24-045083
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/0001493152-24-045083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045083
- JSON: https://secwatch.observer/filing/0001493152-24-045083.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.